Sažetak sa skupa
https://doi.org/10.26800/LV-144-supl2-CR61
Pituitary apoplexy in a patient with atrial fibrillation as a side effect of dabigatran treatment
Dora Cvrtila
; School of Medicine, University of Zagreb
Tina Dušek
; Department of Endocrinology, University Hospital Centre Zagreb
Sažetak
Atrial fibrillation (AF) is the most common heart rhythm abnormality usually present in elderly population significantly increasing the risk for thromboembolic incidents and therefore requiring the long-term treatment with anticoagulant agents. In the last decade, novel ora anticoagulant drugs or NOACs such as dabigatran, apixaban and rivaroxaban have taken over warfarin's role in patients with high risk of blood clothing. They are non peptide, thrombin or coagulation factor Xa inhibitors, consequently patients do not need to control their INR.
Ključne riječi
apoplexy, atrial fibrillation, dabigatran, NO- ACs
Hrčak ID:
279825
URI
Datum izdavanja:
27.4.2022.
Posjeta: 249 *